Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Dividends

An Unconventional 12% Yield Strategy in the Tech Sector

Andreas Sommer by Andreas Sommer
September 23, 2025
in Dividends, ETF, Tech & Software
0
Sierra Stock
0
SHARES
137
VIEWS
Share on FacebookShare on Twitter

For investors accustomed to choosing between the growth potential of technology stocks and the steady income of high-yield investments, Blackrock’s Science & Technology Term Trust (BSTZ) presents a compelling hybrid. This closed-end fund breaks the mold by targeting a double-digit dividend yield from the dynamic technology sector, a feat rarely achieved through conventional means.

A Dual-Pronged Investment Approach

The fund’s ability to generate its current distribution yield of approximately 11.9% stems from a sophisticated, two-part methodology. Unlike standard ETFs or mutual funds, BSTZ operates as a closed-end trust, granting it a significant advantage: access to pre-IPO, private growth companies. This arena is typically reserved for large institutional players, but BSTZ offers a pathway for a broader investor base to participate, with holdings rumored to include firms like Databricks.

A substantial portion of the fund’s impressive income is not derived solely from traditional dividends paid by its portfolio companies. Instead, BSTZ employs an active options strategy. By writing options on its holdings, the fund collects premiums, which are then used to supplement its distribution payments. This technique is designed to enhance overall returns and manage the risk-reward profile of the portfolio.

Should investors sell immediately? Or is it worth buying Sierra?

Trading at a Discount and Operating on a Deadline

A key consideration for value-focused investors is the fund’s market price relative to its underlying assets. BSTZ recently traded at a notable discount of roughly 9-10% to its net asset value (NAV), which stood at $24.65. This price discrepancy means investors can potentially acquire a dollar’s worth of assets for about ninety cents, adding an extra layer of potential value.

Another defining characteristic of BSTZ is its finite lifespan. Structured as a term trust, it has a planned dissolution date approximately twelve years from its inception. This predetermined timeline introduces a distinct strategic element not found in perpetual investment vehicles, as the management team works towards a specific liquidation horizon.

Ultimately, the trust’s performance will be tied to the broader health of the technology sector and the skill of its managers in selecting winning private investments and effectively executing its options income strategy. For those seeking a singular combination of exposure to technological innovation and a strategically-engineered high yield, Blackrock’s BSTZ remains a unique proposition in the market.

Ad

Sierra Stock: Buy or Sell?! New Sierra Analysis from March 25 delivers the answer:

The latest Sierra figures speak for themselves: Urgent action needed for Sierra investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Sierra: Buy or sell? Read more here...

Tags: Sierra
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock
AI & Quantum Computing

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Technology Select Sector SPDR® Fund Stock
AI & Quantum Computing

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

March 25, 2026
Next Post
Astria Therapeutics Stock

Astria Therapeutics Gains Momentum with Promising Eczema Treatment Data

Leadership Shakeup and Major Restructuring at Procter & Gamble

Nio Stock

Nio's Production Struggles Amid Overwhelming ES8 Demand

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com